API – Active Pharmaceutical Ingredient
Active Ingredient: Any component of a drug product intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans or other animals. Active ingredients include those components of the product that may undergo chemical change during the manufacture of the drug product and be present in the drug product in a modified form intended to furnish the specified activity or effect.
Active Pharmaceutical Ingredient: Any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or function of the body. Reference: Manufacturing, Processing, or Holding Active Pharmaceutical Ingredients FDA Guidance
API Starting Material: A raw material, intermediate, or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API Starting Material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement, or produced in-house. API Starting Materials are normally of defined chemical properties and structure. Reference: Manufacturing, Processing, or Holding Active Pharmaceutical Ingredients FDA Guidance
Bulk Drug Substance: According to 21CFR207.3(a)(4) means any substance that is represented for use in a drug and that, when used in the manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished dosage form of the drug, but the term does not include intermediates used in the synthesis of such substances.
API: Latest posts
- Pharmaceuticals have dangerously polluted the world’s rivers, scientists warn
- Minister of Economic Development of the Russian Federation M. Reshetnikov took part in the launch of a production line at the Biokhimik plant of the Promomed Group
- The launch of R&D centre at BratskChemSyntez LLC
- Grindeks invests 800 thousand euros in the creation of a multifunctional site
- Grindeks has reached record high turnover and profit in the first half of 2021